Patients express preferences for bispecific antibodies, highlighting the importance of treatment attributes in managing relapse/refractory diffuse large B-cell lymphoma.
Key Points
Subcutaneous and intravenous bispecific antibodies are critical options for treatment.
Patient preferences emphasize the significance of treatment duration and administration route.
Assessment of preferences aids in patient-centered decision-making for managing DLBCL.
Understanding these preferences may improve therapeutic strategies and patient satisfaction.